The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Ruxolitinib Zentiva ruxolitinib Generic | Zentiva k.s. | Primary Myelofibrosis; Polycythemia Vera; Graft vs Host Disease | 🇪🇺 EU 2026-11-12 | Order → |
| Multibic multibic New active ingredient | Fresenius Medical Care Renal Therapies Group Llc | 🇺🇸 US 2026-11-09 | Order → | |
| NDA221291 New molecular entityPriority review | Bayer Healthcare | 🇺🇸 US 2026-11-09 | Order → | |
| Oxderys doxorubicin hydrochloride New formulation or manufacturer | Avyxa Holdings | 🇺🇸 US 2026-11-09 | Order → | |
| Axycis cisplatin New formulation or manufacturer | Avyxa Holdings, Llc. | 🇺🇸 US 2026-10-29 | Order → | |
| Lucamzi ranibizumab-blrz Biosimilar | Xbrane Biopharma Ab | 🇺🇸 US 2026-10-27 | Order → | |
| Enzeevu aflibercept-abzv Biosimilar | Sandoz Inc | 🇺🇸 US 2026-10-22 | Order → | |
| Lynavoy Linerixibat OrphanAdditional monitoring | GlaxoSmithKline Trading Services Limited | Liver Cirrhosis, Biliary; Pruritus | 🇪🇺 EU 2026-10-22 | Order → |
| Pavblu aflibercept-ayyh Biosimilar | Amgen Inc | 🇺🇸 US 2026-10-22 | Order → | |
| Hibsago bepirovirsen New molecular entityPriority review | Glaxosmithkline Llc | 🇺🇸 US 2026-10-20 | Order → | |
| Calrezdy calcuim chloride New active ingredient | Fresenius Medcl Care | 🇺🇸 US 2026-10-19 | Order → | |
| Cienby sodium ctirate New active ingredient | Fresenius Medcl Care | 🇺🇸 US 2026-10-19 | Order → | |
| Brytly apraclonidine hydrochloride New formulation or manufacturer | Alcon Labs Inc | 🇺🇸 US 2026-10-16 | Order → | |
| Yulzety rivaroxaban New dosage form | Rosemont Pharms | 🇺🇸 US 2026-10-16 | Order → | |
| Evoxac cevimeline hydrochloride New dosage form | Cosette | 🇺🇸 US 2026-10-15 | Order → | |
| Hovilpri pritelivir mesylate New molecular entityPriority review | Aicuris Anti-Infect | 🇺🇸 US 2026-10-09 | Order → | |
| Isovue Readi iopamidol New formulation or manufacturer | Bracco | 🇺🇸 US 2026-10-09 | Order → | |
| Breztri Aerosphere budesonide, formoterol fumarate, glycopyrrolate New formulation or manufacturer | Astrazeneca Ab | 🇺🇸 US 2026-10-08 | Order → | |
| Weltruza olanzapine New formulation or manufacturer | Teva | 🇺🇸 US 2026-10-08 | Order → | |
| Trabectedin trabectedin New formulation or manufacturer | Ever | 🇺🇸 US 2026-10-01 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.